Business Context and Reporting Period
This Form 8-K Current Report was filed by Longeveron Inc. on November 30, 2021, regarding events occurring on December 1 and December 3, 2021. The Company, an emerging growth company incorporated in Delaware, operates in the biotechnology sector with principal executive offices in Miami, Florida.
Key Financial Metrics and Transaction Details
The filing details a private placement completed on December 3, 2021, rather than providing standard periodic financial statements (revenue, profit, or cash flow).
- Gross Proceeds: Approximately $20.5 million.
- Net Proceeds: Approximately $18.6 million (after deducting placement agent fees and expenses).
- Securities Issued: 1,169,288 shares of Class A Common Stock.
- Purchase Price: $17.50 per share.
- Warrants Issued: Purchaser Warrants to buy an equal number of shares (1:1 ratio) at $17.50 per share; Representative Warrants for the placement agent to buy 46,722 shares at $17.50 per share.
- Placement Agent Fees: 7.0% cash fee on gross proceeds, 1.0% cash fee for non-accountable expenses, and reimbursement of up to $100,000 for accountable expenses.
Material Changes and Use of Proceeds
The primary material change is the increase in equity capital and the issuance of new shares and warrants. The filing does not provide comparative financial data against prior periods as it is a transaction report.
The Company intends to use the net cash proceeds to fund:
- Additional research and development.
- Product development.
- General and administrative purposes.
Outlook, Risks, and Contingencies
Registration Rights: The Company is obligated to file a resale registration statement with the SEC promptly following the closing date, but no later than 15 calendar days after the effective date of the Registration Rights Agreement. Failure to file or maintain the effectiveness of this statement may result in the Company paying liquidated damages to investors.
Warrant Terms: The Purchaser Warrants are immediately exercisable, expire five years from issuance, and contain downward pricing adjustment mechanisms subject to a floor.
Legal Disclaimer: The filing explicitly states that representations and warranties in the Purchase Agreement are for risk allocation between parties and should not be relied upon as statements of fact regarding the Company's actual condition.
Investor Verification Checklist
- Verify the dilution impact of the 1,169,288 new shares and associated warrants on existing shareholders.
- Confirm the filing status of the resale registration statement required within 15 days of the agreement's effective date.
- Review the specific terms of the downward pricing adjustment mechanisms in the Purchaser Warrants.
- Monitor future filings for the actual deployment of the $18.6 million in net proceeds toward R&D and product development.